GEN Exclusives

More »

GEN News Highlights

More »
Feb 7, 2011

Speculation Ends as Danaher Announces $6.8B Cash Acquisition of Beckman Coulter

Speculation Ends as Danaher Announces $6.8B Cash Acquisition of Beckman Coulter

$83.5 per share price represents 45% premium on pre-rumour stock value. [Scott Maxwell -]

  • Widespread speculation about who may be seriously looking to snap up Beckman Coulter has ended with the announcement that Danaher is to acquire the diagnostics systems firm for about $6.8 billion in cash, including debt assumed, and net of cash acquired. Danaher is looking to purchase all of Beckman Coulter’s outstanding common stock for $83.50 per share, which represents a 45% premium on its closing price on December 9, 2010, just before rumors that the firm was looking for a potential buyer hit the headlines.

    Danaher will initiate its tender offer within the next seven days through an affiliate company. Once the acquisition has been completed Beckman Coulter will become part of Danaher’s life science and diagnostics segment, joining its existing Leica, AB Sciex, Radiometer, and Molecular Devices businesses.  

    Beckman Coulter says the agreement follows a comprehensive, competitive process, which resulted in the unanimous acceptance of Danaher’s proposal by its board of directors. “We believe this transaction maximizes Beckman Coulter shareholder value while strengthening the company’s position as a leader in biomedical testing to the benefit of our customers and their healthcare patients around the world,” comments Bob Hurley, Beckman Coulter president and CEO.

    Beckman Coulter manufactures diagnostic systems and life science research instruments. The firm says it currently has some 200,000 systems operating in laboratories around the globe. Total third quarter 2010 revenues of $893.8 million, including $112.2 million from its 2009 acquisition of Olympus Diagnostics, was up 8.6% (9.8% at constant currency) on the same quarter in 2009.

    Danaher is a diversified technologies firm with business activities encompassing four reporting segments and comprising seven strategic platforms. These include Medical Technologies (life sciences, diagnostics, and dental), Professional Instrumentation (environmental, test, and measurement), Industrial Technologies (motion, product ID, and focused niche businesses) and Tools & Components (mechanic’s hand tools).

    Danaher’s overall sales for the fourth quarter of 2010 were $3.6 billion, 15% up on Q4 2009. Sales for the full 2010 year reached $13.2 billion, up from just under $11.2 billion in 2009. Sales by its life science and diagnostics business were $681.9 million for the third quarter of 2010, up from $432.1 million during Q4 2009. Full year 2010 sales by the life science and diagnostics division reached $2.3 billion, up from $1.5 billion in 2009.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »